Fenway Health Commends PURPOSE 2 Study Results Demonstrating Efficacy of Twice Yearly PrEP Injections to prevent HIV in gay and bisexual men and transgender and non-binary individuals who have sex with men
Gilead announced today that the PURPOSE 2 study of twice yearly lenacapavir injections as pre-exposure prophylaxis (PrEP) reduced HIV infections by 96% among cisgender gay,